This CPB is revised to state that an allogeneic hematopoietic cell transplantation is considered medically necessary for individuals with intermediate-risk or high-risk myelodysplastic syndrome (MDS), and who have not responded to prior therapy and have an available human leukocyte antigen (HLA)-compatible donor. (The previous version of the CPB required an HLA-matched donor.)